LLY

1,129.82

+4.22%↑

JNJ

231.42

-0.03%↓

ABBV

218.28

+1.73%↑

UNH

381.48

-0.32%↓

MRK

119.8

-0.49%↓

LLY

1,129.82

+4.22%↑

JNJ

231.42

-0.03%↓

ABBV

218.28

+1.73%↑

UNH

381.48

-0.32%↓

MRK

119.8

-0.49%↓

LLY

1,129.82

+4.22%↑

JNJ

231.42

-0.03%↓

ABBV

218.28

+1.73%↑

UNH

381.48

-0.32%↓

MRK

119.8

-0.49%↓

LLY

1,129.82

+4.22%↑

JNJ

231.42

-0.03%↓

ABBV

218.28

+1.73%↑

UNH

381.48

-0.32%↓

MRK

119.8

-0.49%↓

LLY

1,129.82

+4.22%↑

JNJ

231.42

-0.03%↓

ABBV

218.28

+1.73%↑

UNH

381.48

-0.32%↓

MRK

119.8

-0.49%↓

Home・Lista de Ações・Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Abrir

SetorSaúde

1.46 13.18

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.29

Máximo

1.46

Indicadores-chave
By Trading Economics
Rendimento	32M -8.3M
Vendas	-7.5M 37M
EPS	-0.12
Margem de lucro	-22.258
Funcionários	485
EBITDA	509K -38M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+84.5% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-90M 391M
Abertura anterior	-11.72
Fecho anterior	1.46

Sentimento de Notícias

By Acuity

50%

138 / 344 Ranking em Healthcare

Pacific Biosciences of California Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de mai. de 2026, 21:33 UTC

Ganhos

Correction to Salesforce 1Q Sales, Profit Rise Article

27 de mai. de 2026, 21:00 UTC

Aquisições, Fusões, Aquisições de Empresas

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 de mai. de 2026, 20:18 UTC

Ganhos

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 de mai. de 2026, 23:49 UTC

Conversa de Mercado

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

27 de mai. de 2026, 23:08 UTC

Conversa de Mercado

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 de mai. de 2026, 22:21 UTC

Conversa de Mercado

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 de mai. de 2026, 21:29 UTC

Ações em Alta

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 de mai. de 2026, 21:08 UTC

Ganhos

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 de mai. de 2026, 21:02 UTC

Ganhos

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 de mai. de 2026, 20:59 UTC

Aquisições, Fusões, Aquisições de Empresas

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 de mai. de 2026, 20:55 UTC

Ganhos

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

27 de mai. de 2026, 20:48 UTC

Ganhos

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 de mai. de 2026, 20:45 UTC

Ganhos

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 de mai. de 2026, 20:34 UTC

Aquisições, Fusões, Aquisições de Empresas

Webster Financial Stockholders Approve Sale to Banco Santander

27 de mai. de 2026, 20:32 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 de mai. de 2026, 20:32 UTC

Aquisições, Fusões, Aquisições de Empresas

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 de mai. de 2026, 20:32 UTC

Aquisições, Fusões, Aquisições de Empresas

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 de mai. de 2026, 20:30 UTC

Ganhos

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 de mai. de 2026, 20:30 UTC

Aquisições, Fusões, Aquisições de Empresas

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 de mai. de 2026, 20:22 UTC

Ganhos

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 de mai. de 2026, 20:16 UTC

Ganhos

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 de mai. de 2026, 20:13 UTC

Ganhos

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 de mai. de 2026, 20:13 UTC

Ganhos

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 de mai. de 2026, 20:13 UTC

Ganhos

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 de mai. de 2026, 20:12 UTC

Ganhos

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 de mai. de 2026, 20:12 UTC

Ganhos

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Comparação entre Pares

Variação de preço

Pacific Biosciences of California Inc Previsão

Preço-alvo

By TipRanks

84.5% parte superior

Previsão para 12 meses

Média 2.38 USD 84.5%

Máximo 3 USD

Mínimo 1.5 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Pacific Biosciences of California Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

4 ratings

Comprar

Manter

Vender

Com base em 4 analistas que deram avaliações de ações para Pacific Biosciences of California Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

138 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.